| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57000","as_of":"2026-04-18T15:49:14.474663+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/18/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57-000-shares/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57000","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_b070edfc85585c0d","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/18/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57-000-shares/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-18T16:57:55.065269+00:00","extraction_method":"trafilatura","fetched_description":"Key Points57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026.","fetched_title":"Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? | Nasdaq","final_url":"https://www.nasdaq.com/articles/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57000","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57000","source_event_id":"evt_c6c780cdd6af","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"80580044120acc92","kind":"unusual_volume","published_at":"2026-04-18T14:57:38+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-15","2026-04-16","2026-04-09","2026-04-13","2026-03"],"entities":[{"asset_class":"equity","name":"Adaptive Biotechnologies Corporation","relevance":"high","symbol":"ADPT","type":"company"},{"asset_class":"person","name":"Julie Rubinstein","relevance":"high","symbol":"","type":"person"},{"asset_class":"exchange","name":"NASDAQ","relevance":"medium","symbol":"NASDAQ","type":"exchange"}],"event_type":"other","information_gaps":["No volume ratio vs baseline/average is provided in the supplied text, so unusual volume cannot be quantified.","No explicit statement is made about whether the volume change (if any) is confirmed by broader news; the article focuses on insider transactions.","The article does not cite a specific company/news catalyst tied to the insider sale; the most likely catalyst is inferred as option exercise/liquidity rather than a fundamental event."],"key_facts":["Rubinstein sold 57,180 shares of ADPT common stock across multiple open-market transactions ending April 16, 2026.","The total transaction value was approximately $826,000 (per the article).","The weighted average sale price was around $14.45 per share (per SEC Form 4 filing, as stated).","The article states the post-transaction value was based on the April 16, 2026 market close of $14.08.","The sale represented 12.29% of Rubinstein\u2019s direct holdings at the time, reducing her directly held common stock to 408,160 shares.","The shares sold were acquired through exercise of options immediately prior to sale; the article states no indirect holdings or gifts were involved.","The article describes the transaction as involving exercise of 44,166 options with all resulting shares immediately sold, characterizing it as a liquidity event rather than a disposition from long-term holdings.","The article states Rubinstein had completed seven administrative (option-related) transactions since March 2026, and that the scale of recent sales tracked declining available share capacity.","The article also states that during April 9\u201313 (four-day period), Rubinstein exercised options and reduced direct holdings by 27,736 shares.","The article mentions Rubinstein ended April 16 with 408,160 shares and 148,770 stock options (as stated)."],"numeric_claims":[{"label":"shares_sold","value":"57,180"},{"label":"transaction_value_usd","value":"~826,000"},{"label":"sale_window_end_date","value":"2026-04-16"},{"label":"weighted_avg_sale_price_usd","value":"~14.45"},{"label":"post_transaction_market_close_usd","value":"14.08"},{"label":"percent_of_holdings_sold","value":"12.29%"},{"label":"direct_shares_after_sale","value":"408,160"},{"label":"options_exercised","value":"44,166"},{"label":"direct_shares_reduced_apr_9_to_apr_13","value":"27,736"},{"label":"stock_options_after_apr_16","value":"148,770"}],"primary_claim":"Julie Rubinstein sold 57,180 ADPT shares in open-market transactions between April 14 and April 16, 2026 after exercising 44,166 options, reducing her direct holdings by 12.29% to 408,160 shares.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Adaptive Biotechnologies (ADPT) President and COO Julie Rubinstein sold 57,180 shares in open-market transactions from April 14\u201316, 2026 after exercising options. The article frames this as an option-related liquidity event rather than a discretionary long-term sell-off, with no explicit news catalyst cited.","topics":["insider trading","SEC Form 4","option exercise","executive transactions","Adaptive Biotechnologies","MRD diagnostics"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026.","tickers":["ADPT"],"title":"Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?","url":"https://www.fool.com/coverage/filings/2026/04/18/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57-000-shares/"}... |